权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Early prediction of colorectal liver metastases treatment response with ultrasound microvessel imaging

超声微血管成像早期预测结直肠肝转移治疗反应

基本信息

批准号：
10084826
负责人：
Pengfei Song
金额：
$ 24.9万
依托单位：
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-03-01 至 2023-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10084826
关键词：
3-Dimensional Animals Assessment tool Blinking Blood Vessels Blood flow Cancer Etiology Cessation of life Clinical Clinical Research Clinical Trials Clinical assessments Colorectal Colorectal Cancer Combined Modality Therapy Development Diagnostic radiologic examination Disease Progression Dose Early identification Early treatment Event Excision Histology Human Image Imaging Techniques Imaging technology Immunotherapy Liver Liver neoplasms Magnetic Resonance Imaging Malignant neoplasm of liver Measurement Measures Medical Metastatic Neoplasm to the Liver Methods Microbubbles Modeling Morphology Movement Neoadjuvant Therapy Neoplasm Metastasis Operative Surgical Procedures Oryctolagus cuniculus Patients Penetration Performance Phase Physiologic pulse Play Reference Standards Resolution Role Scanning Speed Surrogate Endpoint Techniques Technology Time Toxic effect Treatment Efficacy Treatment Protocols Treatment outcome Ultrasonography United States Vascular blood supply anti-cancer antiangiogenesis therapy antitumor effect base cancer cell chemotherapy clinical imaging clinically significant colon cancer patients colorectal cancer treatment cost effective data acquisition density early detection biomarkers hemodynamics imaging modality improved individualized medicine ineffective therapies microCT mortality novel novel therapeutics nutrition predicting response predictive marker real-time images recruit response treatment group treatment optimization treatment response treatment strategy tumor

项目摘要

Project Summary/Abstract Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Metastasized colorectal cancer (mCRC), primarily in liver, is the predominate factor for the mortality of CRC patients. Treatment of CRC liver metastases is essential to the survival of mCRC patients. Currently, anti-angiogenesis therapy plays a significant role in the treatment of CRC liver metastases. Early and accurate prediction of response to anti-angiogenesis therapy is of vital clinical significance because: 1) early identification of nonresponders can expedite the adjustment of treatment regimens to avoid disease progression and spare patients from unnecessary toxicity and medical expense of ineffective therapies; 2) reliable response assessment can help individualize treatment strategy and optimize dose and time course of therapy to achieve maximal treatment efficacy; 3) an early and accurate predictive biomarker is also very beneficial to development of new therapy agents by providing a reliable surrogate endpoint for clinical trials. At present, however, a reliable treatment response assessment tool for anti-angiogenesis therapy does not exist clinically. To fill this gap, here we propose to develop a novel ultrasound microvessel imaging technology, VesselQuest, to early predict anti-angiogenesis therapy response by examining tumor micro-vasculature with quantitative hemodynamic and morphologic measurements. VesselQuest can accurately measure a wide dynamic range of microvessel flow speed and offers a spatial super-resolution that cannot be achieved by current clinical imaging modalities. Similar to other ultrasound techniques, VesselQuest is also noninvasive, safe, and cost effective. These features of VesselQuest provide excellent potential for clinical assessment of colorectal liver metastases treatment response to anti-angiogenic therapy. Aims 1 and 2 of this study will be focused on technical development of VesselQuest, paving the way for the aims 3 and 4 of the study which will be focused on validating VesselQuest on an animal tumor model and conducting a pilot clinical study on CRC liver metastases patients to assess treatment response to anti-angiogenesis therapy. Successful completion of this project will provide a novel and viable technology for early prediction of anti-angiogenic therapy to improve treatment outcome and survival of CRC liver metastases patients. Technologies developed for this project can also be used for assessment of emerging novel treatment method such as immunotherapy.

项目摘要/摘要结直肠癌(CRC)是美国癌症死亡的第二大原因。转移的结直肠癌是导致结直肠癌患者死亡的主要因素，主要发生在肝脏。结直肠癌肝转移的治疗对多发性结直肠癌患者的生存至关重要。目前，抗血管生成治疗在结直肠癌肝转移的治疗中发挥着重要作用。及早准确地预测抗血管生成治疗的反应具有重要的临床意义，因为：1)早期发现无反应者可以加快调整治疗方案，以避免疾病进展和备用患者不必要的毒性和无效治疗的医疗费用；2)可靠的反应评估可以帮助个性化治疗策略，优化治疗剂量和时间进程，以实现 3)早期、准确的预测生物标志物也非常有益于通过为临床试验提供可靠的替代终点，开发新的治疗药物。目前，然而，临床上尚不存在用于抗血管生成治疗的可靠的疗效评估工具。为了填补这一空白，我们建议开发一种新的超声微血管成像技术VesselQuest，定量检测肿瘤微血管早期预测抗血管生成治疗反应血液动力学和形态学测量。VesselQuest可以精确测量大范围的动态范围微血管血流速度，并提供了目前临床无法达到的空间超分辨率成像方式。与其他超声波技术类似，VesselQuest也是一种无创、安全和成本低廉的技术有效。VesselQuest的这些特点为结直肠肝脏的临床评估提供了极好的潜力转移瘤治疗对抗血管生成治疗的反应。本研究的目标1和目标2将重点放在 VesselQuest的技术开发，为将重点研究的目标3和4铺平道路 VesselQuest在动物肿瘤模型上的验证和对结直肠癌肝脏的初步临床研究以评估转移性患者对抗血管生成治疗的反应。成功完成这项工作该项目将为早期预测抗血管生成治疗提供一种新的可行的技术来提高结直肠癌肝转移患者的治疗结果和生存期。为该项目开发的技术可以也可用于评估新兴的治疗方法，如免疫疗法。

项目成果

期刊论文数量（35）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（1）

Contrast-Free Super-Resolution Power Doppler (CS-PD) Based on Deep Neural Networks.

DOI：
10.1109/tuffc.2023.3304527
发表时间：
2023-10
期刊：
IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL
影响因子：
3.6
作者：
You, Qi;Lowerison, Matthew R.;Shin, Yirang;Chen, Xi;Sekaran, Nathiya Vaithiyalingam Chandra;Dong, Zhijie;Llano, Daniel Adolfo;Anastasio, Mark A.;Song, Pengfei
通讯作者：
Song, Pengfei

Hadamard-Encoded Multipulses for Contrast-Enhanced Ultrasound Imaging.